Imeik Technology Development Co - Asset Resilience Ratio

Latest as of March 2026: 26.02%

Imeik Technology Development Co (300896) has an Asset Resilience Ratio of 26.02% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥2.38 Billion
≈ $347.77 Million USD Cash + Short-term Investments

Total Assets

CN¥9.13 Billion
≈ $1.34 Billion USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2025)

This chart shows how Imeik Technology Development Co's Asset Resilience Ratio has changed over time. Check Imeik Technology Development Co (300896) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Imeik Technology Development Co's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Imeik Technology Development Co.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥2.38 Billion 26.02%
Total Liquid Assets CN¥2.38 Billion 26.02%

Asset Resilience Insights

  • Very High Liquidity: Imeik Technology Development Co maintains exceptional liquid asset reserves at 26.02% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Imeik Technology Development Co Industry Peers by Asset Resilience Ratio

Compare Imeik Technology Development Co's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Hangzhou Alltest Biotech Co. Ltd. A
SHG:688606
Medical Instruments & Supplies 11.88%
Daxor Corporation
NASDAQ:DXR
Medical Instruments & Supplies 65.10%
Ansell Ltd
AU:ANN
Medical Instruments & Supplies 7.53%
Nanosonics Ltd
AU:NAN
Medical Instruments & Supplies 46.84%
SDI Ltd
AU:SDI
Medical Instruments & Supplies 3.36%
Austco Healthcare Ltd
AU:AHC
Medical Instruments & Supplies 15.90%
Trajan Group Holdings Ltd
AU:TRJ
Medical Instruments & Supplies 0.29%
Osteopore Ltd
AU:OSX
Medical Instruments & Supplies 22.60%

Annual Asset Resilience Ratio for Imeik Technology Development Co (2014–2025)

The table below shows the annual Asset Resilience Ratio data for Imeik Technology Development Co.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 24.18% CN¥2.15 Billion
≈ $315.23 Million
CN¥8.91 Billion
≈ $1.30 Billion
-10.32pp
2024-12-31 34.50% CN¥2.88 Billion
≈ $421.12 Million
CN¥8.34 Billion
≈ $1.22 Billion
+16.93pp
2023-12-31 17.57% CN¥1.20 Billion
≈ $176.20 Million
CN¥6.85 Billion
≈ $1.00 Billion
+6.33pp
2022-12-31 11.24% CN¥703.69 Million
≈ $102.97 Million
CN¥6.26 Billion
≈ $915.82 Million
+4.22pp
2021-12-31 7.03% CN¥370.51 Million
≈ $54.22 Million
CN¥5.27 Billion
≈ $771.47 Million
-10.99pp
2020-12-31 18.01% CN¥841.57 Million
≈ $123.15 Million
CN¥4.67 Billion
≈ $683.61 Million
+11.10pp
2016-12-31 6.92% CN¥21.71 Million
≈ $3.18 Million
CN¥313.86 Million
≈ $45.93 Million
-5.34pp
2015-12-31 12.25% CN¥21.16 Million
≈ $3.10 Million
CN¥172.64 Million
≈ $25.26 Million
-7.15pp
2014-12-31 19.41% CN¥20.43 Million
≈ $2.99 Million
CN¥105.29 Million
≈ $15.41 Million
--
pp = percentage points

About Imeik Technology Development Co

SHE:300896 China Medical Instruments & Supplies
Market Cap
$4.69 Billion
CN¥32.06 Billion CNY
Market Cap Rank
#3698 Global
#516 in China
Share Price
CN¥105.95
Change (1 day)
-2.80%
52-Week Range
CN¥85.50 - CN¥201.00
All Time High
CN¥570.69
About

Imeik Technology Development Co.,Ltd. engages in the research and development, and transformation of biomedical materials and biopharmaceutical products in China. The company offers aesthetic medicine products, such as cross-linked sodium hyaluronate gel with PLLA-b-PEG microsphere; poly facial implant thread; medical sodium hyaluronate-hydroxypropyl methylcellulose gel; sodium hyaluronate compos… Read more